AGIO
Agios Pharmaceuticals, Inc.
$41.23
-1.56 (-3.65%)
At close · Jul 10
Market Cap
$2.43B
Shares
59,471,609
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$54.03M
+48%
FY2025
Net Income
-$412.78M
-161.3%
FY2025
Gross Margin
88.26%
-0.3pp
FY2025
Operating Margin
-873.87%
+292.6pp
FY2025
Diluted EPS
-$7.12
-161.2%
FY2025
Operating Cash Flow
-$372.98M
+4.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $45M – $50M | $66.05M | $54.03M | $36.5M | $26.82M | $14.24M | $0 | $0 | $117.91M | $94.39M | $43.01M | $69.89M | $59.12M | $65.36M | $25.55M | $25.11M | $21.84M | |
| — | $6.58M | $6.35M | $4.17M | $2.88M | $1.7M | $0 | $0 | $1.32M | $1.4M | $0 | $0 | — | — | — | — | — | |
| — | $59.47M | $47.68M | $32.33M | $23.94M | $12.54M | $0 | $0 | $116.6M | $92.99M | $43.01M | $69.89M | — | — | — | — | — | |
| — | — | 88.26% | 88.59% | 89.26% | 88.03% | — | — | 98.88% | 98.52% | 100% | 100% | — | — | — | — | — | |
| — | $347.94M | $339.54M | $301.29M | $295.53M | $279.91M | $256.97M | $220.81M | $214.26M | $341.32M | $292.68M | $220.16M | $141.83M | $100.37M | $54.5M | $41.04M | $31.25M | |
| — | — | — | — | — | — | — | — | — | — | $71.12M | $50.71M | $35.99M | $19.12M | $9.93M | $7.06M | $7.22M | |
| — | $187.06M | $180.28M | $156.78M | $119.9M | $121.67M | $121.45M | $115.11M | $102.01M | $114.15M | $71.12M | $50.71M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $8.09M | $7.17M | $6.43M | — | — | — | — | — | — | |
| — | $529.25M | — | — | — | — | — | — | — | $456.87M | $363.81M | $270.88M | $177.82M | $119.49M | $64.43M | $48.1M | $38.47M | |
| — | $541.58M | $526.16M | $462.24M | $418.31M | $403.29M | $378.42M | $335.92M | $316.27M | $456.87M | $363.81M | — | — | — | — | — | — | |
| — | -$475.53M | -$472.13M | -$425.74M | -$391.49M | -$389.05M | -$378.42M | -$335.92M | -$316.27M | -$362.48M | -$320.79M | -$200.99M | -$118.7M | -$54.13M | -$38.88M | -$23M | -$16.63M | |
| — | — | -873.87% | -1166.47% | -1459.52% | -2732.07% | — | — | -268.22% | -384.03% | -745.84% | -287.57% | -200.78% | -82.83% | -152.2% | -91.59% | -76.16% | |
| — | — | — | — | — | — | — | — | -$308.18M | -$355.31M | -$314.36M | — | — | — | — | — | — | |
| — | — | — | — | — | $12.79M | $836K | $6.61M | $14.86M | $16.45M | $6.12M | $2.51M | $968K | $203K | $55K | $69K | $132K | |
| — | $822K | $1.96M | $6.49M | $6.06M | $6.75M | $14.43M | $0 | $0 | — | — | — | — | — | — | — | — | |
| — | — | -$413.8M | $717.97M | -$352.09M | -$231.8M | -$356.51M | -$329.31M | -$301.41M | -$346.03M | -$314.67M | -$198.47M | -$117.73M | -$53.93M | -$38.83M | -$22.93M | -$16.5M | |
| — | — | -$1.02M | $44.24M | $0 | $0 | — | — | $0 | $0 | $0 | $0 | $0 | -$426K | $579K | -$2.82M | $7.21M | |
| — | -$422.6M | -$412.78M | $673.73M | -$352.09M | -$231.8M | $1.6B | -$327.37M | -$411.47M | -$346.03M | -$314.67M | -$198.47M | -$117.73M | -$53.5M | -$39.41M | -$20.1M | -$23.71M | |
| — | — | -764.01% | 1845.92% | -1312.63% | -1627.82% | — | — | -348.97% | -366.61% | -731.6% | -283.97% | -199.14% | -81.86% | -154.25% | -80.07% | -108.56% | |
| — | $1.6B | — | — | — | — | — | — | — | — | — | — | -$117.73M | -$53.5M | -$43.57M | -$27.29M | -$26.81M | |
| — | -$423.28M | -$409.07M | $672.65M | -$339.99M | -$243.14M | $1.6B | -$327.47M | -$409.1M | -$346.81M | -$315.75M | -$198.47M | -$117.99M | -$53.58M | -$39.39M | -$20.13M | -$23.68M | |
| USD/shares | — | — | -$7.12 | $11.86 | -$6.33 | -$4.23 | $26.55 | -$4.74 | -$6.86 | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$7.12 | $11.64 | -$6.33 | -$4.23 | $26.55 | -$4.74 | -$6.86 | — | — | — | — | — | — | — | — |
| shares | — | — | 57.97M | 56.81M | 55.65M | 54.79M | 60.45M | 69M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.42M | 3.4M | 3.01M |
| shares | — | — | 57.97M | 57.89M | 55.65M | 54.79M | 60.45M | 69M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.42M | 3.4M | 3.01M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $54,028,000 | $36,498,000 | $26,823,000 | $11,740,000 | $0 | $0 | $59,851,000 | $13,841,000 |
| Collaboration Revenue Other | — | — | — | — | — | $3,571,000 | $8,262,000 | $12,670,000 |
| Collaboration Revenue Related Party | — | — | — | — | — | $68,274,000 | $39,257,000 | $60,661,000 |
| Commercialization Activity | — | — | — | — | — | $3,927,000 | $3,303,000 | $3,744,000 |
| Committee Participation | — | — | — | — | — | $0 | $0 | $0 |
| Development Activities | — | — | — | — | — | $0 | $0 | $1,342,000 |
| Research Services | — | — | — | — | — | $64,347,000 | $35,954,000 | $40,575,000 |
| License And Service | — | — | — | — | — | $0 | $0 | $15,000,000 |
| Royalty | — | — | — | $2,500,000 | $0 | $0 | $10,542,000 | $7,215,000 |